Versartis reports positive results from Phase 1 trial of VRS-317
The results of the 60-day, placebo-controlled, single-ascending dose trial demonstrated that the single doses of VRS-317 were safe and well tolerated while adverse events that were considered drug
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.